I wish I knew about this earlier. David said that to me just after his treatment ended, disheartened and exhausted. And it broke my heart because I hear it far too often.Because earlier could have protected his strength. Earlier could have improved his outcomes. And earlier could have changed everything.But earlier isn't only about time. It's about perspective and what becomes visible when we change our vantage point. Like standing up on the escarment, we stop, we breathe, and the whole coastline comes into ...

Core Insights - Eikon Therapeutics, Inc. reported significant progress in 2025, including a successful IPO that strengthened its financial position and enabled advancement of multiple clinical programs [2][7]. Pipeline Updates - EIK1001, a dual-agonist for Toll-like receptors 7 and 8, completed enrollment in the TeLuRide-005 Phase 2 study for non-small cell lung cancer, with data expected in the second half of 2026 [3][4]. - EIK1003 and EIK1004, next-generation PARP1 inhibitors, are under evaluation in various trials, with EIK1003 expected to initiate a new cohort in the second half of 2026 [5]. - EIK1005, a WRN helicase inhibitor, has shown in vitro activity in MSI-high cancer cells and is currently in a Phase 1/2 trial [4][5]. Financial Results - As of December 31, 2025, Eikon had cash, cash equivalents, and marketable securities totaling $336.0 million, bolstered by an IPO that raised $381.2 million in February 2026 [7][17]. - Research and Development (R&D) expenses for Q4 2025 were $65.2 million, a 21% increase from Q4 2024, driven by clinical trial activities and increased operational costs [8]. - General and Administrative (G&A) expenses for Q4 2025 were $17.9 million, a 29% increase from the previous year, primarily due to higher compensation costs and depreciation expenses [9]. - The net loss attributable to common stockholders for Q4 2025 was $79.7 million, compared to $64.9 million in the prior year, with a total net loss of $333.6 million for the full year 2025 [10][16].

Core Viewpoint - BeyondSpring Inc. is set to present its research on Plinabulin at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting its innovative approach to cancer treatment [1]. Group 1: Company Overview - BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for significant unmet medical needs [3]. - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer (NSCLC) and other indications [3]. - Plinabulin operates through a novel mechanism as a dendritic cell maturation agent, which supports both anti-cancer activity and immune modulation, aiming to enhance tumor sensitivity to checkpoint inhibitors [3]. Group 2: Presentation Details - The poster presentation will take place on April 21, 2026, from 2 PM to 5 PM PT at the San Diego Convention Center [4]. - The session will focus on immunology, specifically under the category of T Cell Engagers 2 / Antibody-Drug Conjugates 1 [4]. - The poster will be numbered 5597 and located at Poster Board Number 16 [4].

Core Insights - Ascentage Pharma reported significant advancements in its commercialization strategy and clinical pipeline for 2025, particularly with the launch of Lisaftoclax and the expansion of Olverembatinib's coverage in China's National Reimbursement Drug List (NRDL) [2][6][19] Financial Performance - Total revenue for 2025 was US$82.1 million, a decrease of 41.5% from US$134.3 million in 2024, primarily due to the absence of intellectual property revenue recorded in 2024 [19] - Product sales of Olverembatinib increased by 80.6% year-over-year to US$62.2 million, while sales of Lisaftoclax reached US$10.1 million during its first five months post-launch [6][19] - Selling and distribution expenses rose by 80.4% to US$50.6 million, attributed to increased commercialization activities [20] - Research and development expenses increased by 20.1% to US$162.7 million, reflecting higher clinical trial costs [21] - The company reported a loss of US$177.7 million for the year, compared to a loss of US$55.6 million in 2024 [25] Product and Pipeline Updates - Olverembatinib is the first third-generation BCR-ABL1 TKI approved in China for chronic myeloid leukemia (CML) patients with specific mutations and resistance to earlier treatments [3][32] - Lisaftoclax, a novel Bcl-2 inhibitor, was launched in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is undergoing multiple Phase III trials [34] - Nine registrational Phase III clinical trials are currently in progress for both Olverembatinib and Lisaftoclax, with several cleared by the FDA and EMA [6][12] Market and Commercialization Strategy - The number of hospitals where Olverembatinib is available increased by 12.4% to 825, with a notable 36.5% increase in hospitals on formulary for the drug [7] - The company aims to actively pursue the inclusion of Lisaftoclax in China's NRDL in 2026 [24] Upcoming Milestones - Continued enrollment in ongoing clinical trials for both Olverembatinib and Lisaftoclax, including POLARIS-1, POLARIS-2, POLARIS-3, and various GLORA studies [9][12][24] - Plans to initiate clinical studies for APG-3288, a novel BTK degrader, with an open-label Phase I study expected to commence [18]

Group 1 - Biomea Fusion, Inc. (NASDAQ:BMEA) is recognized as one of the top 10 stocks under $5 with the potential to triple in value [1] - As of March 19, 2026, nearly 88% of analysts maintain bullish ratings on BMEA, with a consensus price target of $6.00, suggesting a potential upside of 415.02% [2] - The company reported positive findings from its Phase II COVALENT-111 study of icovamenib for type 2 diabetes, which has contributed to the positive analyst sentiment [3] Group 2 - In the COVALENT-111 trial, 267 patients were assessed, with 163 completing at least 80% of their dosage before a clinical hold; significant declines in HbA1c were observed, particularly in severe insulin-deficient individuals, with reductions of up to 1.50% at Week 52 [4] - The trial results indicated improvements in beta-cell activity and sustained glucose control nine months post-therapy, with no significant side effects or treatment-related discontinuations [4] - Biomea Fusion focuses on covalent small-molecule therapeutics for treating cancers and metabolic disorders, with icovamenib targeting diabetes and BMF-219 addressing oncogenic signaling in genetically characterized tumors [5]

Core Viewpoint - Merck is pursuing a $6.7 billion acquisition of Terns Pharmaceuticals to enhance its cancer treatment portfolio, but the deal may face challenges due to Terns' promising drug data for chronic myeloid leukemia treatment, TERN-701 [1][2]. Group 1: Acquisition Details - The acquisition values Terns Pharmaceuticals at $6.7 billion, which includes $5.7 billion of net acquired cash, representing a 31% premium to the 60-day volume-weighted price of Terns stock and a 42% premium to the 90-day stock price [3]. - Merck's Chairman and CEO, Robert Davis, stated that the acquisition builds on Merck's growing presence in hematology with TERN-701, which is seen as a potential best-in-class candidate for chronic myeloid leukemia treatment [3]. Group 2: Market Reaction and Stock Performance - Following the acquisition announcement, Terns' stock rose over 5% to $52.72, nearing the $53 per share takeover price, while Merck's stock increased more than 2% to $119.56, reflecting a significant rise of over 50% since late September [2][3]. - Analysts project TERN-701 could generate $297 million in sales by 2030, indicating strong market potential for the drug [4]. Group 3: Drug Efficacy and Competitive Landscape - TERN-701 has shown a 64% major molecular response in patients with refractory chronic myeloid leukemia, suggesting a significant reduction in cancer cells, which positions it to potentially disrupt the current treatment landscape dominated by Novartis' Scemblix [6][4]. - The prevalence of chronic myeloid leukemia is expected to continue increasing at a double-digit rate into the next decade, further enhancing the market opportunity for TERN-701 [5]. Group 4: Potential for Competitive Bids - There is speculation that the acquisition proposal by Merck may not fully reflect the potential of TERN-701, leading to the possibility of another bidder emerging with a more attractive offer [7][8].

Core Insights - BeyondSpring Inc. reported significant clinical and operational progress in 2025, particularly with its lead program Plinabulin, and highlighted strategic developments related to its equity interest in SEED Therapeutics [2][3] Clinical and Operational Progress - The company advanced its Phase 3 Plinabulin program for non-small cell lung cancer (NSCLC) and generated meaningful clinical data [3] - SEED Therapeutics initiated its first clinical trial following IND clearance in both the U.S. and China, marking a critical milestone [3] - Plinabulin demonstrated a statistically significant overall survival benefit in the DUBLIN-3 study compared to docetaxel alone, with a median overall survival improvement of 2.5 months [6][11] - The DUBLIN-4 confirmatory trial is planned to further evaluate Plinabulin in a biomarker-selected patient population [8][9] Financial Developments - BeyondSpring completed a $30 million Series A-3 financing and appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer [19] - The company reported a net loss of $8.7 million for 2025, slightly improved from a net loss of $8.9 million in 2024 [19][24] - Cash, cash equivalents, and short-term investments totaled $12.6 million as of December 31, 2025 [19] Future Outlook - BeyondSpring is focused on advancing the DUBLIN-4 trial for Plinabulin and supporting SEED's Phase 1a clinical program for ST-01156 in solid tumors [4] - The company aims to create long-term value for shareholders through its strategic initiatives and clinical advancements [4]

Core Viewpoint - Merck has announced its acquisition of Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which represents a premium of 31% over the 60-day average stock price and 42% over the 90-day average stock price as of March 24, 2026 [2][3]. Company Overview - Merck, known as MSD outside the U.S. and Canada, is enhancing its oncology portfolio through the acquisition of Terns, which focuses on developing innovative therapies for chronic myeloid leukemia (CML) [2][3]. - Terns Pharmaceuticals is a clinical-stage oncology company with a lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor [2][4]. Acquisition Details - The acquisition is subject to Terns' stockholders tendering their shares and regulatory approvals, with an expected closing in the second quarter of 2026 [5]. - The transaction will be accounted for as an asset acquisition, resulting in a charge of approximately $5.8 billion, or about $2.35 per share, impacting both second quarter and full year 2026 financial results [5]. Product Development - TERN-701 is currently in Phase 1/2 development, specifically in the CARDINAL trial for patients with Philadelphia chromosome-positive CML who have experienced treatment failure or intolerance [3][11]. - The FDA granted Orphan Drug Designation for TERN-701 in March 2024, indicating its potential significance in treating CML [3]. Clinical Trial Insights - Early clinical trials of TERN-701 have shown promising results, including encouraging rates of major molecular response and low incidence of severe adverse events [4][11]. - The CARDINAL trial has completed its dose escalation phase with no dose-limiting toxicities observed, and the expansion phase is currently underway [11]. Market Need - There remains a significant need for innovative therapies in CML, as existing treatments may not provide optimal responses for all patients [5][12]. - TERN-701 aims to offer a differentiated option for patients, potentially improving efficacy and safety compared to current treatments [5][10].

Core Insights - Fennec Pharmaceuticals reported record commercial growth for its product PEDMARK, with significant increases in patient support metrics and adoption in both new and existing accounts [7] - The company achieved record net product sales of $44.6 million for 2025, up from $29.6 million in 2024, and fourth-quarter net product sales of $13.8 million, an increase from $7.9 million in the prior-year quarter [6] - Management emphasized the importance of expanding the customer-facing team and improving operational infrastructure to enhance patient conversion rates, which improved from 50% in Q1 to 70% in Q4 [2][4] Marketing and Patient Support - The company is launching initiatives to engage young adult testicular cancer patients, including a partnership for the Indy 500 event and a significant presence at the ASCO meeting [1] - Fennec HEARS, the full-service patient support program, achieved record performance in Q4 with all-time highs in patient enrollments and conversion rates [3] Financial Performance - The fourth quarter marked the fifth consecutive quarter of net product sales growth, attributed to broader account growth and improved conversion and adherence among PEDMARK patients [5] - Selling and marketing expenses rose to $6.1 million in Q4 from $3.9 million a year earlier, while general and administrative expenses increased to $8.9 million from $4.2 million [12][13] - Fennec ended 2025 with $36.8 million in cash and cash equivalents, driven by approximately $42 million in net proceeds from equity offerings [14] Strategic Developments - A settlement of U.S. patent litigation related to PEDMARK was announced, preventing Cipla from entering the market with a generic product until September 1, 2033, which is expected to save the company "multiple millions of dollars" annually [16] - The company is expanding its medical affairs organization and generating new clinical evidence to support PEDMARK's use, with encouraging feedback from clinicians [8][10] Future Outlook - The company anticipates cash operating expenses to rise from approximately $35 million in 2025 to about $50 million in 2026, reflecting investments in commercial and medical functions [18] - Norgine launched PEDMARQSI in the U.K. and Germany in 2025, with plans for 8-10 launches in 2026, expected to contribute to royalty revenues [19] - Ongoing clinical trials in Japan and evaluations at various cancer institutes are expected to enhance the understanding and application of PEDMARK [20][21]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with a projected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism of action and promising preclinical results [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients who have run out of standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]